Diagnostik und Therapie der Polymyalgia rheumatica

Translated title of the contribution: Diagnostics and treatment of polymyalgia rheumatica

C. Dejaco, Eric Lawrence Matteson, F. Buttgereit

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Polymyalgia rheumatica (PMR) is the most common autoimmune inflammatory disease in older persons with an average age of onset of 73 years. Typical symptoms include acute or subacute bilateral shoulder pain with severe stiffness and often neck and bilateral hip pain. Giant cell arteritis (GCA) occurs in approximately 20 % of cases and up to two thirds of patients with GCA have symptoms of PMR. There are many disease which mimic PMR, elderly onset rheumatoid arthritis is frequently misdiagnosed as PMR. Although there are no specific laboratory tests, C‑reactive protein and erythrocyte sedimentation rates are elevated in over 90 % of patients. The diagnosis may be aided by imaging, especially ultrasonography and magnetic resonance imaging (MRI). Treatment currently consists of glucocorticoids at an initial dose of 12.5–25 mg prednisone equivalent daily. Treatment duration is typically 2‑3 years but may be longer. Under certain conditions low-dose methotrexate can be used as adjuvant therapy.

Translated title of the contributionDiagnostics and treatment of polymyalgia rheumatica
Original languageGerman
Pages (from-to)687-700
Number of pages14
JournalZeitschrift fur Rheumatologie
Issue number7
StatePublished - Sep 1 2016


  • Arthritis
  • Autoimmune diseases
  • Epidemiology
  • Monitoring
  • Treatment

ASJC Scopus subject areas

  • Rheumatology


Dive into the research topics of 'Diagnostics and treatment of polymyalgia rheumatica'. Together they form a unique fingerprint.

Cite this